Arvinas reports Q2 2026 results after first-ever FDA approval of a PROTAC drug

Arvinas said the FDA's approval of VEPPANU marked the first time the agency approved a PROteolysis TArgeting Chimera, or PROTAC, a type of heterobifunctional protein degrader.¹ The approval covers adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy, as detected by an FDA-authorized test¹, part of Arvinas's collaboration with Pfizer.

Following approval, Arvinas entered a license agreement giving Rigel Pharmaceuticals exclusive global rights to develop, manufacture, and commercialize VEPPANU.¹ Separately, the National Comprehensive Cancer Network added vepdegestrant (VEPPANU) to its Clinical Practice Guidelines in Oncology as a Category 2A option for HR-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer after endocrine therapy plus a CDK4/6 inhibitor.¹

On the pipeline, Arvinas said it expects to share early monotherapy dose-escalation data for ARV-393 in relapsed/refractory non-Hodgkin lymphoma at a medical congress in the second half of 2026¹, with additional B- and T-cell lymphoma data and DLBCL combination data with glofitamab expected in mid-2027.¹ For ARV-102, the company plans to share additional biomarker data from the Parkinson's disease Phase 1 trial at the International Congress on Parkinson's Disease and Movement Disorders in October 2026¹ and continue discussions with health authorities on starting trials in progressive supranuclear palsy in 2027.¹ ARV-027 will continue multiple-dose enrollment with initial muscle androgen-receptor degradation data expected in the first half of 2027.¹ ARV-6723, the company's first immuno-oncology candidate, is set to begin Phase 1 enrollment in advanced solid tumors in the third quarter of 2026.¹ For ARV-806, Arvinas completed dose-escalation enrollment in KRAS G12D solid tumors and reiterated plans to share initial data in the second half of 2026¹, while it said it would seek an out-licensing partner for any further trials, including dose expansion or combination studies.¹

On finances, Arvinas said its cash, cash equivalents, and marketable securities as of June 30, 2026 are expected to fund operations into the second half of 2028.¹ That position stood at $567.9 million as of June 30, 2026, down from $685.4 million at the end of 2025.¹